Recent content by jondoeuk

Not yet as additional clinical trials are needed. Hopefully, more will start in the next few months.

Also of interest, the Reuters article on this has the following statement about the potential price of VDPHL01: ''The company said Nutrafol, a Unilever-backed hair-growth supplement that costs about $90 a month or about $1,000 a year, is a good price benchmark for its drug.''...

Veradermics announced positive top-line results from Part A of its phase three clinical trial (Study ‘304’). It entailed over 500 males with mild-to-moderate pattern hair loss who took oral VDPHL01 (extended-release oral minoxidil)...

It is safer. It looks to be more effective as well.

Rubedo announced plans to initiate a Phase 2a trial of RLS-1496 for androgenetic alopecia in October 2026...

Amplifica raised $26 million in a Series B Preferred Stock financing round. Of particular note, one of the investors is Eli Lilly (US), which also invested in Absci (US) earlier this year...

Amplifica published five-month results of a 61-person trial of AMP-303, described as a novel polysaccharide. https://www.jidonline.org/article/S0022-202X(25)01992-X/fulltext The male subjects (all aged 18-45) with mild to moderate androgenetic alopecia (Norwood III-IV) were divided into two...

Amplifica's AMP-303 phase one trial results came out: ''A statistically significant percentage of study subjects showed a greater than 15% increase in non-vellus hair count from baseline compared to placebo at 60 days post-treatment, and a greater than 10% increase compared to placebo at 150...

More here https://www.wired.com/story/a-hair-loss-study-raises-new-questions-about-aging-cells/

Kintor plans to initiate a phase IIb/III clinical trial of pyrilutamide in combination with minoxidil for the treatment of male androgenetic alopecia in China this year.

GT20029 1% BIW (twice per week application).

''In an independent ex vivo human Androgenetic Alopecia model — conducted using intact human hair follicles from male patients with Androgenetic Alopecia, challenged with dihydrotestosterone (DHT) to replicate the follicular miniaturization environment seen in Androgenetic Alopecia patients — RLS‑1496 demonstrated statistically and highly...

Rubedo Life Sciences announced that it would start a clinical trial in 2026 to test its GPX4 modulator to treat hair loss...

Yes.

''The study met its primary safety endpoint and secondary pharmacokinetic endpoint: the drug was well tolerated with no systemic absorption of PP405 detected in the blood, underscoring a robust safety profile.''...